A Phase I/II, Open Label Study to Evaluate Safety, Tolerability and Therapeutic Effects of Transplantation of Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients.

Trial Profile

A Phase I/II, Open Label Study to Evaluate Safety, Tolerability and Therapeutic Effects of Transplantation of Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 May 2016

At a glance

  • Drugs Neurotrophic factor producing mesenchymal stem cell therapy BrainStorm Cell therapeutics (Primary) ; Neurotrophic factor producing mesenchymal stem cell therapy BrainStorm Cell therapeutics (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 10 May 2016 According to a BrainStorm Cell Therapeutics media release, combined results from this and a phase IIa trial (CTP 700228777) were presented at the ISRASTEM 2016 and 6th Israel Stem Cell Society (ISCS) joint annual meeting.
    • 29 Mar 2016 According to a BrainStorm media release, combined results from this and a phase IIa trial (CTP 700228777) will be presented at the ISRASTEM 2016 and the 6th International Israel Stem Cell Society Joint Annual Meeting
    • 11 Jan 2016 Combined results of this and a phase IIa trial (CTP 700228777) published in the JAMA Neurology, according to a BrainStorm Cell Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top